Onderneming ContraVir Pharmaceuticals Inc Nasdaq
Aandelen
US21234W1036
Biotechnologie & Medisch Onderzoek
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
John Cavan
CEO | Chief Executive Officer | 65 | 01-01-16 |
Daren Ure
CTO | Chief Tech/Sci/R&D Officer | - | 03-10-19 |
Stephen Kilmer
IRC | Investor Relations Contact | - | - |
Daniel Trepanier
PRN | Corporate Officer/Principal | - | 03-10-19 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
John Brancaccio
CHM | Chairman | 76 | 15-05-13 |
Timothy Block
BRD | Director/Board Member | 69 | 26-11-13 |
Kaouthar Lbiati
BRD | Director/Board Member | 45 | 27-06-22 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 0 | 1 688 | 0 | 0 | 99,69 % |
Aandeel B | 1 | 5 472 451 | 5 455 670 ( 99,69 %) | 0 | |
Aandeel C | 0 | 85 581 | 0 | 0 |
Bedrijfsgegevens
Hepion Pharmaceuticals, Inc.
399 Thornall Street 1st Floor
08837, Edison
+732 902 4000
http://www.hepionpharma.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+7,52% | 111 mld. | |
+11,38% | 106 mld. | |
-12,64% | 22,24 mld. | |
+0,44% | 21,25 mld. | |
-4,18% | 18,97 mld. | |
-37,85% | 18,52 mld. | |
-8,58% | 16,81 mld. | |
+37,41% | 12,54 mld. | |
-23,95% | 8,09 mld. |